HIV感染者代谢物谱与BMI、腰臀比及抗逆转录病毒治疗的关系
瑞士HIV队列研究纳入1302名≥45岁HIV感染者,分析非靶向代谢物谱与BMI、腰臀比及抗逆转录病毒治疗(ART)的关联。发现94种代谢物与BMI相关、66种与腰臀比相关,156、173和60种代谢物分别与非核苷逆转录酶抑制剂、蛋白酶抑制剂和整合酶链转移抑制剂暴露相关。
要点
- BMI和腰臀比与多种氨基酸/肽类代谢物强相关。
- 不同ART药物类别及个体药物具有特异性代谢扰动模式。
- 替诺福韦艾拉酚胺与替诺福韦二吡呋酯关联的代谢物多数不重叠。
核心结论
- 在瑞士HIV感染者中,非靶向代谢物谱揭示多种与不同ART药物未报道的关联,以及与BMI的既往报道关联。
研究设计与样本
- 瑞士HIV队列研究纳入1302名年龄≥45岁的HIV感染者,分析非靶向代谢物谱与BMI、腰臀比及当前ART方案(按第三药物分类及个体药物)的关联。
主要发现
- 94种代谢物与BMI相关,66种与腰臀比相关,最强关联见于氨基酸/肽类。
- 156、173和60种代谢物分别与非核苷逆转录酶抑制剂、蛋白酶抑制剂和整合酶链转移抑制剂暴露相关,多数关联见于碳水化合物。
- 识别出依非韦伦、奈韦拉平、洛匹那韦、阿扎那韦和埃替拉韦的特异性代谢扰动模式。
- 替诺福韦艾拉酚胺关联的多数代谢物与替诺福韦二吡呋酯不重叠,反之亦然。
- 31种代谢物与BMI或腰臀比及ART暴露均相关;未发现与既往齐多夫定或司他夫定暴露相关的代谢物谱,也未发现ART药物类别与BMI的交互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a major concern in people with HIV (PWH). How obesity and antiretroviral therapy (ART) are associated with specific metabolite profiles in PWH is not well described. METHODS: We included Swiss HIV Cohort Study participants aged ≥45 years. We analyzed untargeted metabolite profiles and their association with BMI, waist-hip ratio (WHR), and ART, both current ART regimen categorized based on the "third drug" plus individual ART drugs. Metabolite profiles were clustered with hierarchical clustering and visualized as heatmaps and Uniform Manifold Approximation and Projection. RESULTS: We analyzed 1821 putative metabolite ions in 1302 PWH (median age 55 years, 78% male, 94% suppressed HIV RNA, median BMI 24.6kg/m2, 46% overweight/obese). 94 metabolites were associated with BMI and 66 with WHR; the strongest associations were found with amino acids/peptides. 156, 173, and 60 metabolites were associated with exposure to non-nucleoside reverse transcriptase inhibitors, protease-inhibitors, and integrase strand transfer inhibitors, respectively; most associations were found among carbohydrates. We identified specific patterns of metabolic perturbation for efavirenz, nevirapine, lopinavir, atazanavir, and elvitegravir. Most metabolites associated with tenofovir alafenamide were not associated with tenofovir disoproxil fumarate and vice versa. 31 metabolites were associated with either BMI or WHR and ART-exposure. We found no evidence of any metabolite profiles associated with past zidovudine or stavudine exposure or any interactions between ART drug classes and BMI, after adjusting for multiple testing. DISCUSSION: In PWH from Switzerland, untargeted metabolite profiling revealed multiple unreported associations with different ART agents, and previously reported associations with BMI.
引用
- Labarile M, Schoepf IC, Pasin C, et al. Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV: the Swiss HIV Cohort Study. J Infect Dis. 2025. PMID: 40858302. doi:10.1093/infdis/jiaf438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。